Review



molm-13 acute monocytic leukemia (aml) cell line  (STEMCELL Technologies Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STEMCELL Technologies Inc molm-13 acute monocytic leukemia (aml) cell line
    Molm 13 Acute Monocytic Leukemia (Aml) Cell Line, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/molm-13+acute+monocytic+leukemia+(aml)+cell+line/molm+13+acute+monocytic+leukemia++aml++cell+line/pmc08306075-284-3-16
    Average 90 stars, based on 1 article reviews
    molm-13 acute monocytic leukemia (aml) cell line - by Bioz Stars, 2026-08
    90/100 stars

    Images



    Similar Products

    acute monocytic leukemia aml m5a cell line molm13  (DSMZ)
    97
    DSMZ acute monocytic leukemia aml m5a cell line molm13
    Ex vivo armed T cells with multiple BsAbs (multi-EATs). (A) Surface BsAb density on multi-EAT was analyzed using anti-human IgG Fc-specific antibody and quantified using quantum beads. Geometric mean fluorescence intensities (MFIs) of EATs were measured with increasing arming doses of each BsAb, and BsAb density (MFI) of EAT was referenced to antibody-binding capacity (ABC). (B) In vitro cytotoxicity of multi-EATs and CD33-EATs against CD33(+) <t>MOLM13</t> cell line at increasing E:T ratios and increasing BsAb arming doses. The optimal BsAb densities on T cells were extrapolated from the ADTC assays. (C) In vitro cytotoxicity of multi-EATs was tested against a panel of tumor cell lines (E:T ratio was 10:1) and compared with mono-EATs. ABC, antibody binding capacity; ADTC, antibody-dependent T cell-mediated cytotoxicity; BsAbs, bispecific antibodies; EATs, ex vivo armed T cells; E:T, effector to target.
    Acute Monocytic Leukemia Aml M5a Cell Line Molm13, supplied by DSMZ, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/molm-13+acute+monocytic+leukemia+(aml)+cell+line/MOLM-13/pmc08796264-46-41-48
    Average 97 stars, based on 1 article reviews
    acute monocytic leukemia aml m5a cell line molm13 - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier
    molm-13 acute monocytic leukemia (aml) cell line  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc molm-13 acute monocytic leukemia (aml) cell line
    Ex vivo armed T cells with multiple BsAbs (multi-EATs). (A) Surface BsAb density on multi-EAT was analyzed using anti-human IgG Fc-specific antibody and quantified using quantum beads. Geometric mean fluorescence intensities (MFIs) of EATs were measured with increasing arming doses of each BsAb, and BsAb density (MFI) of EAT was referenced to antibody-binding capacity (ABC). (B) In vitro cytotoxicity of multi-EATs and CD33-EATs against CD33(+) <t>MOLM13</t> cell line at increasing E:T ratios and increasing BsAb arming doses. The optimal BsAb densities on T cells were extrapolated from the ADTC assays. (C) In vitro cytotoxicity of multi-EATs was tested against a panel of tumor cell lines (E:T ratio was 10:1) and compared with mono-EATs. ABC, antibody binding capacity; ADTC, antibody-dependent T cell-mediated cytotoxicity; BsAbs, bispecific antibodies; EATs, ex vivo armed T cells; E:T, effector to target.
    Molm 13 Acute Monocytic Leukemia (Aml) Cell Line, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/molm-13+acute+monocytic+leukemia+(aml)+cell+line/molm+13+acute+monocytic+leukemia++aml++cell+line/pmc08306075-284-3-16
    Average 90 stars, based on 1 article reviews
    molm-13 acute monocytic leukemia (aml) cell line - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Ex vivo armed T cells with multiple BsAbs (multi-EATs). (A) Surface BsAb density on multi-EAT was analyzed using anti-human IgG Fc-specific antibody and quantified using quantum beads. Geometric mean fluorescence intensities (MFIs) of EATs were measured with increasing arming doses of each BsAb, and BsAb density (MFI) of EAT was referenced to antibody-binding capacity (ABC). (B) In vitro cytotoxicity of multi-EATs and CD33-EATs against CD33(+) MOLM13 cell line at increasing E:T ratios and increasing BsAb arming doses. The optimal BsAb densities on T cells were extrapolated from the ADTC assays. (C) In vitro cytotoxicity of multi-EATs was tested against a panel of tumor cell lines (E:T ratio was 10:1) and compared with mono-EATs. ABC, antibody binding capacity; ADTC, antibody-dependent T cell-mediated cytotoxicity; BsAbs, bispecific antibodies; EATs, ex vivo armed T cells; E:T, effector to target.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies

    doi: 10.1136/jitc-2021-003771

    Figure Lengend Snippet: Ex vivo armed T cells with multiple BsAbs (multi-EATs). (A) Surface BsAb density on multi-EAT was analyzed using anti-human IgG Fc-specific antibody and quantified using quantum beads. Geometric mean fluorescence intensities (MFIs) of EATs were measured with increasing arming doses of each BsAb, and BsAb density (MFI) of EAT was referenced to antibody-binding capacity (ABC). (B) In vitro cytotoxicity of multi-EATs and CD33-EATs against CD33(+) MOLM13 cell line at increasing E:T ratios and increasing BsAb arming doses. The optimal BsAb densities on T cells were extrapolated from the ADTC assays. (C) In vitro cytotoxicity of multi-EATs was tested against a panel of tumor cell lines (E:T ratio was 10:1) and compared with mono-EATs. ABC, antibody binding capacity; ADTC, antibody-dependent T cell-mediated cytotoxicity; BsAbs, bispecific antibodies; EATs, ex vivo armed T cells; E:T, effector to target.

    Article Snippet: Neuroblastoma cell line, IMR-32 (ATCC Cat# CCL-127, RRID:CVCL_0346), osteosarcoma cell line, 143B (ATCC Cat# CRL-8303, RRID:CVCL_2270), primitive neuroectodermal tumor cell line TC-32 (RRID:CVCL-7151), breast cancer cell line HCC1954 (ATCC Cat# CRL-2338, RRID:CVCL_1259), gastric cancer cell line NCI-N87 (ATCC Cat# CRL-2338, RRID:CVCL_1259), acute monocytic leukemia (AML-M5a) cell line MOLM13 (DSMZ Cat# ACC-554, RRID:CVCL_2119), prostate cancer cell line LNCaP-AR (ATCC Cat# CRL-1740, RRID:CVCL_1379), and melanoma cell line M14 (NCI-DTP Cat# M14, RRID:CVCL_1395) were used for experiments.

    Techniques: Ex Vivo, Fluorescence, Binding Assay, In Vitro